Olmesartan Medoxomil and Hydrochlorothiazide

Warning

Fetal toxicity: When pregnancy is detected, discontinue olmesartan medoxomil and hydrochlorothiazide tablets as soon as possible.

Contraindications

• Hypersensitivity to any component of olmesartan medoxomil and hydrochlorothiazide tablets
• Anuria
• Coadministration with aliskiren in patients with diabetes

Adverse Reactions

• Dizziness
• Nausea
• Hyperuricemia
• Upper respiratory infection

General Guidance

Adjust dose after 2 to 4 weeks, as needed, to a maximum of 40 mg / 25 mg olmesartan / hydrochlorothiazide

Pregnancy

• Discontinue olmesartan medoxomil and hydrochlorothiazide tablets as soon as possible when pregnancy is detected
• Fetal toxicity risks

Nursing Mothers

• It is not known whether olmesartan is excreted in human milk
• Thiazides appear in human milk
• Decision should be made whether to discontinue nursing or discontinue olmesartan medoxomil and hydrochlorothiazide tablets

Pediatric Use

• Safety and effectiveness not established in pediatric patients
• Neonates with a history of in utero exposure to olmesartan medoxomil and hydrochlorothiazide tablets may require support of blood pressure and renal perfusion

Geriatric Use

• Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects
• Dose selection should be cautious, usually starting at the low end of the dosing range